Vol. 6 No. 3 (2026)
Reimbursement Reviews

Talazoparib (Talzenna)

decorative image of the issue cover

Published March 27, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses talazoparib (Talzenna), 0.1 mg and 0.25 mg oral capsules.
  • Indication: In combination with enzalutamide for the treatment of adult patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.